Steven Gourlay

Dr Gourlay has more than 30 years of experience in the development of novel therapeutics and brings skills and experience to Actinogen. Formerly the founding Chief Medical Officer (CMO) at US-based Principia Biopharma Inc., Dr Gourlay was responsible for the supervision of multiple pre-clinical, first-in-human, phase 2 and 3 clinical trial programs in orphan immunological diseases, multiple sclerosis and cancer. The data generated by these trials, and Dr Gourlay's roadshow presentations, supported a NASDAQ IPO of Principia Biopharma Inc. in 2018 - subsequently followed by an acquisition by Sanofi for US$3.7 billion in 2020. Prior to Principia Biopharma, Dr Gourlay was a Partner at GBS Venture Partners, the Australian specialist life sciences and healthcare venture capital firm, where he contributed to multiple clinical stage therapeutic companies including Elastagen, Spinifex and Peplin. Dr Gourlay has regulatory drug experience with the US Food and Drug Administration (FDA), European Medicines.